Robert Wolfe
Concepts (639)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle Proteins | 90 | 2024 | 321 | 14.280 |
Why?
| | Muscle, Skeletal | 111 | 2024 | 804 | 13.280 |
Why?
| | Dietary Proteins | 51 | 2025 | 252 | 13.010 |
Why?
| | Amino Acids, Essential | 49 | 2024 | 133 | 10.140 |
Why?
| | Amino Acids | 62 | 2025 | 377 | 8.880 |
Why?
| | Protein Biosynthesis | 28 | 2021 | 258 | 4.990 |
Why?
| | Dietary Supplements | 33 | 2024 | 465 | 4.220 |
Why?
| | Nutritional Requirements | 18 | 2025 | 67 | 4.100 |
Why?
| | Burns | 28 | 2022 | 163 | 4.050 |
Why?
| | Exercise | 29 | 2024 | 547 | 3.330 |
Why?
| | Aging | 27 | 2020 | 701 | 3.310 |
Why?
| | Diet | 16 | 2024 | 587 | 3.260 |
Why?
| | Phenylalanine | 49 | 2022 | 132 | 3.260 |
Why?
| | Triglycerides | 18 | 2020 | 165 | 3.220 |
Why?
| | Sarcopenia | 10 | 2022 | 98 | 2.930 |
Why?
| | Proteins | 15 | 2022 | 348 | 2.930 |
Why?
| | Milk Proteins | 10 | 2016 | 77 | 2.910 |
Why?
| | Isotopes | 6 | 2022 | 25 | 2.860 |
Why?
| | Insulin | 39 | 2024 | 479 | 2.620 |
Why?
| | Meals | 13 | 2024 | 63 | 2.600 |
Why?
| | Glucose | 18 | 2022 | 355 | 2.510 |
Why?
| | Insulin Resistance | 19 | 2024 | 275 | 2.450 |
Why?
| | Humans | 215 | 2025 | 52483 | 2.190 |
Why?
| | Leucine | 14 | 2023 | 114 | 2.080 |
Why?
| | Bed Rest | 15 | 2020 | 36 | 2.080 |
Why?
| | Body Composition | 27 | 2022 | 338 | 2.010 |
Why?
| | Anabolic Agents | 7 | 2019 | 44 | 1.980 |
Why?
| | Digestion | 5 | 2020 | 29 | 1.980 |
Why?
| | Energy Intake | 11 | 2024 | 174 | 1.910 |
Why?
| | Kinetics | 31 | 2022 | 626 | 1.910 |
Why?
| | Liver | 12 | 2021 | 1156 | 1.880 |
Why?
| | Male | 147 | 2024 | 26761 | 1.850 |
Why?
| | Blood Glucose | 30 | 2020 | 473 | 1.790 |
Why?
| | Skin | 10 | 2015 | 422 | 1.710 |
Why?
| | Aged | 66 | 2024 | 10121 | 1.630 |
Why?
| | Energy Metabolism | 19 | 2024 | 302 | 1.620 |
Why?
| | Feeding Behavior | 8 | 2024 | 192 | 1.610 |
Why?
| | Weight Loss | 6 | 2018 | 248 | 1.550 |
Why?
| | Resistance Training | 11 | 2024 | 101 | 1.550 |
Why?
| | Obesity | 14 | 2024 | 1162 | 1.490 |
Why?
| | Nutrition Policy | 7 | 2012 | 39 | 1.490 |
Why?
| | Rabbits | 22 | 2015 | 375 | 1.470 |
Why?
| | Palmitates | 7 | 2022 | 29 | 1.440 |
Why?
| | Female | 114 | 2024 | 28171 | 1.420 |
Why?
| | Animals | 54 | 2024 | 13505 | 1.400 |
Why?
| | Muscle Strength | 13 | 2024 | 130 | 1.340 |
Why?
| | Adult | 80 | 2024 | 14161 | 1.340 |
Why?
| | Carbon Isotopes | 22 | 2017 | 70 | 1.310 |
Why?
| | Lipid Metabolism | 7 | 2020 | 187 | 1.300 |
Why?
| | Leg | 21 | 2011 | 120 | 1.280 |
Why?
| | Arginine | 9 | 2022 | 182 | 1.280 |
Why?
| | Postprandial Period | 11 | 2024 | 73 | 1.260 |
Why?
| | Hyperinsulinism | 6 | 2015 | 30 | 1.250 |
Why?
| | Wound Healing | 6 | 2008 | 219 | 1.200 |
Why?
| | Models, Biological | 13 | 2024 | 735 | 1.180 |
Why?
| | Dietary Carbohydrates | 11 | 2024 | 90 | 1.180 |
Why?
| | Double-Blind Method | 17 | 2021 | 713 | 1.180 |
Why?
| | Fatty Acids, Nonesterified | 10 | 2020 | 39 | 1.160 |
Why?
| | Heart Failure | 3 | 2019 | 565 | 1.100 |
Why?
| | Wounds and Injuries | 6 | 2008 | 309 | 1.030 |
Why?
| | Food, Formulated | 4 | 2019 | 42 | 1.020 |
Why?
| | Hypoglycemic Agents | 7 | 2013 | 211 | 0.980 |
Why?
| | Middle Aged | 60 | 2024 | 13028 | 0.970 |
Why?
| | Valerates | 3 | 2017 | 39 | 0.940 |
Why?
| | Isotope Labeling | 4 | 2019 | 57 | 0.920 |
Why?
| | Critical Illness | 8 | 2016 | 317 | 0.920 |
Why?
| | Overweight | 4 | 2018 | 224 | 0.850 |
Why?
| | Swine | 8 | 2019 | 428 | 0.840 |
Why?
| | Cross-Over Studies | 13 | 2022 | 238 | 0.830 |
Why?
| | Pyruvic Acid | 3 | 2021 | 21 | 0.810 |
Why?
| | Amino Acids, Branched-Chain | 3 | 2017 | 43 | 0.790 |
Why?
| | Hyperglycemia | 6 | 2020 | 88 | 0.780 |
Why?
| | Mitochondria, Muscle | 6 | 2024 | 40 | 0.770 |
Why?
| | Nitric Oxide | 4 | 2015 | 249 | 0.760 |
Why?
| | Geriatric Assessment | 2 | 2021 | 117 | 0.750 |
Why?
| | Whole Body Imaging | 2 | 2019 | 26 | 0.720 |
Why?
| | Food Analysis | 1 | 2021 | 28 | 0.720 |
Why?
| | Deuterium | 11 | 2019 | 46 | 0.720 |
Why?
| | Kidney | 2 | 2021 | 707 | 0.710 |
Why?
| | Gluconeogenesis | 1 | 2020 | 4 | 0.710 |
Why?
| | Lipoproteins, VLDL | 4 | 2024 | 9 | 0.710 |
Why?
| | Lactic Acid | 2 | 2021 | 78 | 0.700 |
Why?
| | Actinidia | 1 | 2020 | 7 | 0.700 |
Why?
| | Glycolysis | 1 | 2021 | 73 | 0.690 |
Why?
| | Hydrocortisone | 8 | 2020 | 111 | 0.680 |
Why?
| | Young Adult | 18 | 2024 | 4329 | 0.680 |
Why?
| | Muscular Atrophy | 4 | 2021 | 71 | 0.670 |
Why?
| | Food, Fortified | 2 | 2021 | 27 | 0.650 |
Why?
| | Aged, 80 and over | 13 | 2021 | 3392 | 0.650 |
Why?
| | Caloric Restriction | 3 | 2020 | 38 | 0.650 |
Why?
| | Muscle Contraction | 5 | 2019 | 117 | 0.650 |
Why?
| | Renal Dialysis | 9 | 2015 | 179 | 0.640 |
Why?
| | Metformin | 3 | 2005 | 76 | 0.630 |
Why?
| | Elder Nutritional Physiological Phenomena | 2 | 2015 | 7 | 0.620 |
Why?
| | Human Growth Hormone | 2 | 2017 | 50 | 0.610 |
Why?
| | Nutritional Status | 6 | 2021 | 137 | 0.610 |
Why?
| | DNA | 4 | 2007 | 549 | 0.610 |
Why?
| | Stress, Physiological | 4 | 2019 | 183 | 0.610 |
Why?
| | Beverages | 4 | 2019 | 57 | 0.600 |
Why?
| | Regional Blood Flow | 10 | 2015 | 109 | 0.590 |
Why?
| | Muscle Cells | 4 | 2009 | 22 | 0.590 |
Why?
| | Adrenergic beta-Antagonists | 5 | 2006 | 110 | 0.590 |
Why?
| | Sepsis | 6 | 2019 | 239 | 0.590 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 316 | 0.570 |
Why?
| | Critical Care | 2 | 2017 | 222 | 0.570 |
Why?
| | Lipids | 7 | 2022 | 155 | 0.560 |
Why?
| | Glucose Intolerance | 4 | 2020 | 27 | 0.560 |
Why?
| | Fenofibrate | 2 | 2007 | 17 | 0.540 |
Why?
| | Cardiovascular Diseases | 4 | 2021 | 490 | 0.540 |
Why?
| | Hypolipidemic Agents | 2 | 2007 | 29 | 0.540 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2007 | 339 | 0.540 |
Why?
| | Eating | 9 | 2024 | 159 | 0.540 |
Why?
| | Time Factors | 18 | 2021 | 2968 | 0.540 |
Why?
| | Skin Transplantation | 3 | 2007 | 44 | 0.530 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 3 | 2005 | 64 | 0.520 |
Why?
| | Fatty Acids | 6 | 2013 | 149 | 0.510 |
Why?
| | Kidney Failure, Chronic | 7 | 2015 | 210 | 0.510 |
Why?
| | Weight Lifting | 3 | 2004 | 30 | 0.500 |
Why?
| | Homeostasis | 3 | 2014 | 201 | 0.500 |
Why?
| | Adolescent | 24 | 2024 | 6739 | 0.500 |
Why?
| | Proteolysis | 5 | 2020 | 101 | 0.490 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 59 | 0.480 |
Why?
| | Citrulline | 1 | 2015 | 104 | 0.470 |
Why?
| | Diet, Reducing | 1 | 2015 | 36 | 0.470 |
Why?
| | Epidermis | 2 | 2006 | 32 | 0.460 |
Why?
| | Nutritional Support | 1 | 2014 | 35 | 0.460 |
Why?
| | Testosterone | 5 | 2007 | 141 | 0.460 |
Why?
| | Zinc | 2 | 2022 | 56 | 0.450 |
Why?
| | Metabolomics | 1 | 2016 | 150 | 0.450 |
Why?
| | Ileum | 3 | 2019 | 88 | 0.450 |
Why?
| | Adipose Tissue | 4 | 2013 | 204 | 0.440 |
Why?
| | Meat | 4 | 2024 | 60 | 0.440 |
Why?
| | Protein Stability | 2 | 2017 | 45 | 0.440 |
Why?
| | Gas Chromatography-Mass Spectrometry | 4 | 2016 | 69 | 0.440 |
Why?
| | Administration, Oral | 9 | 2009 | 451 | 0.430 |
Why?
| | Up-Regulation | 1 | 2015 | 454 | 0.430 |
Why?
| | Radiopharmaceuticals | 1 | 2014 | 204 | 0.420 |
Why?
| | Nitrogen Isotopes | 7 | 2022 | 38 | 0.420 |
Why?
| | Biological Availability | 4 | 2019 | 108 | 0.410 |
Why?
| | Muscle Development | 1 | 2013 | 24 | 0.410 |
Why?
| | PPAR alpha | 3 | 2007 | 59 | 0.410 |
Why?
| | Infusions, Intravenous | 9 | 2021 | 220 | 0.400 |
Why?
| | Frail Elderly | 1 | 2012 | 36 | 0.400 |
Why?
| | Body Mass Index | 13 | 2022 | 689 | 0.400 |
Why?
| | Activities of Daily Living | 2 | 2014 | 182 | 0.390 |
Why?
| | Palmitoyl Coenzyme A | 4 | 2015 | 4 | 0.390 |
Why?
| | Biopsy | 9 | 2011 | 605 | 0.390 |
Why?
| | Glutamine | 2 | 2003 | 176 | 0.380 |
Why?
| | Fibroblasts | 2 | 2004 | 355 | 0.380 |
Why?
| | Glycerol | 4 | 2009 | 19 | 0.370 |
Why?
| | Nutritional Physiological Phenomena | 4 | 2018 | 22 | 0.370 |
Why?
| | Mitochondria | 4 | 2024 | 430 | 0.370 |
Why?
| | Oxidation-Reduction | 8 | 2024 | 326 | 0.370 |
Why?
| | Hormones | 5 | 2019 | 59 | 0.360 |
Why?
| | Extracellular Fluid | 3 | 2006 | 14 | 0.360 |
Why?
| | Phospholipids | 2 | 2020 | 59 | 0.350 |
Why?
| | Threonine | 3 | 2022 | 15 | 0.350 |
Why?
| | Arthroplasty, Replacement, Hip | 2 | 2021 | 266 | 0.350 |
Why?
| | Metabolism | 5 | 2020 | 25 | 0.350 |
Why?
| | Heart Rate | 3 | 2007 | 318 | 0.340 |
Why?
| | Physical Endurance | 3 | 2024 | 34 | 0.340 |
Why?
| | Nitrogen | 5 | 2022 | 70 | 0.340 |
Why?
| | Immobilization | 2 | 2007 | 15 | 0.340 |
Why?
| | Hospitalization | 3 | 2012 | 736 | 0.340 |
Why?
| | Cytokines | 4 | 2007 | 623 | 0.330 |
Why?
| | Nutritive Value | 3 | 2017 | 29 | 0.320 |
Why?
| | Muscular Diseases | 3 | 2006 | 63 | 0.320 |
Why?
| | Body Weight | 7 | 2025 | 523 | 0.320 |
Why?
| | Cardiac Output | 2 | 2006 | 42 | 0.320 |
Why?
| | Biological Transport | 8 | 2013 | 160 | 0.320 |
Why?
| | Cattle | 3 | 2024 | 205 | 0.310 |
Why?
| | Propanolamines | 2 | 2006 | 14 | 0.310 |
Why?
| | Lung Compliance | 2 | 2006 | 9 | 0.310 |
Why?
| | Urea | 4 | 2022 | 82 | 0.310 |
Why?
| | Models, Animal | 4 | 2016 | 234 | 0.300 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 17 | 0.300 |
Why?
| | Musculoskeletal Physiological Phenomena | 2 | 2013 | 7 | 0.300 |
Why?
| | Propranolol | 3 | 2006 | 78 | 0.300 |
Why?
| | Area Under Curve | 6 | 2008 | 180 | 0.300 |
Why?
| | Blood Flow Velocity | 6 | 2007 | 95 | 0.300 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2018 | 11 | 0.300 |
Why?
| | Fibrinogen | 2 | 2005 | 34 | 0.300 |
Why?
| | Diet, Protein-Restricted | 3 | 2024 | 9 | 0.290 |
Why?
| | Case-Control Studies | 7 | 2010 | 1201 | 0.290 |
Why?
| | Protein Kinase C | 1 | 2008 | 68 | 0.290 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 153 | 0.290 |
Why?
| | Reproducibility of Results | 6 | 2016 | 1229 | 0.290 |
Why?
| | Soft Tissue Injuries | 1 | 2008 | 17 | 0.290 |
Why?
| | Intracellular Fluid | 2 | 2005 | 11 | 0.290 |
Why?
| | Hemoglobins | 2 | 2006 | 112 | 0.290 |
Why?
| | RNA, Transfer, Amino Acyl | 1 | 2007 | 1 | 0.290 |
Why?
| | Treatment Outcome | 15 | 2020 | 5422 | 0.280 |
Why?
| | Absorptiometry, Photon | 5 | 2020 | 162 | 0.280 |
Why?
| | Alanine | 3 | 2004 | 44 | 0.280 |
Why?
| | Acetates | 1 | 2007 | 52 | 0.280 |
Why?
| | Insulin, Long-Acting | 1 | 2007 | 2 | 0.270 |
Why?
| | Intermittent Claudication | 1 | 2007 | 13 | 0.270 |
Why?
| | Herpesvirus 4, Human | 1 | 2007 | 43 | 0.270 |
Why?
| | Child | 19 | 2022 | 7248 | 0.270 |
Why?
| | Carbon Dioxide | 1 | 2007 | 97 | 0.270 |
Why?
| | Peripheral Vascular Diseases | 1 | 2007 | 23 | 0.270 |
Why?
| | Virus Activation | 1 | 2007 | 39 | 0.270 |
Why?
| | Pseudomonas Infections | 2 | 2017 | 54 | 0.270 |
Why?
| | Acyl Coenzyme A | 2 | 2006 | 8 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2009 | 1378 | 0.270 |
Why?
| | Muscles | 2 | 2006 | 107 | 0.270 |
Why?
| | Malnutrition | 3 | 2021 | 90 | 0.260 |
Why?
| | Creatine | 2 | 2016 | 39 | 0.260 |
Why?
| | Carnitine | 2 | 2010 | 68 | 0.260 |
Why?
| | Dermis | 2 | 2004 | 19 | 0.260 |
Why?
| | Hemodynamics | 2 | 2017 | 263 | 0.260 |
Why?
| | Mafenide | 1 | 2006 | 1 | 0.260 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2006 | 6 | 0.260 |
Why?
| | Valine | 2 | 2003 | 57 | 0.260 |
Why?
| | Living Donors | 1 | 2006 | 27 | 0.250 |
Why?
| | Military Personnel | 2 | 2019 | 177 | 0.250 |
Why?
| | Hormone Replacement Therapy | 1 | 2005 | 21 | 0.250 |
Why?
| | Mitochondrial Proteins | 3 | 2022 | 89 | 0.250 |
Why?
| | Shock, Hemorrhagic | 1 | 2005 | 12 | 0.240 |
Why?
| | Fatty Liver | 2 | 2024 | 142 | 0.240 |
Why?
| | Brain Injuries | 1 | 2007 | 159 | 0.240 |
Why?
| | Mitochondrial Dynamics | 3 | 2024 | 23 | 0.240 |
Why?
| | Walkers | 1 | 2004 | 2 | 0.240 |
Why?
| | Models, Theoretical | 2 | 2016 | 185 | 0.230 |
Why?
| | Blood Coagulation | 1 | 2005 | 64 | 0.230 |
Why?
| | PPAR delta | 1 | 2024 | 2 | 0.230 |
Why?
| | Physical Conditioning, Animal | 2 | 2024 | 59 | 0.230 |
Why?
| | Dynamins | 1 | 2024 | 9 | 0.230 |
Why?
| | Caseins | 1 | 2004 | 78 | 0.230 |
Why?
| | Glucose Clamp Technique | 5 | 2009 | 15 | 0.230 |
Why?
| | Malonyl Coenzyme A | 2 | 2010 | 7 | 0.230 |
Why?
| | Hyperandrogenism | 1 | 2024 | 1 | 0.220 |
Why?
| | Physical Exertion | 1 | 2004 | 46 | 0.220 |
Why?
| | Exercise Tolerance | 1 | 2004 | 46 | 0.220 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2024 | 9 | 0.220 |
Why?
| | Metabolic Clearance Rate | 5 | 2019 | 69 | 0.220 |
Why?
| | Dietary Fats | 2 | 2017 | 130 | 0.220 |
Why?
| | Egg Proteins | 2 | 2021 | 18 | 0.220 |
Why?
| | Disabled Persons | 1 | 2004 | 72 | 0.220 |
Why?
| | Developed Countries | 1 | 2024 | 17 | 0.220 |
Why?
| | Cell Division | 4 | 2006 | 291 | 0.220 |
Why?
| | Child, Preschool | 10 | 2022 | 4076 | 0.220 |
Why?
| | Inulin | 1 | 2003 | 10 | 0.220 |
Why?
| | Disease Models, Animal | 3 | 2019 | 1478 | 0.220 |
Why?
| | Injections, Intravenous | 2 | 2014 | 138 | 0.210 |
Why?
| | Glycine | 4 | 2004 | 75 | 0.210 |
Why?
| | Algorithms | 5 | 2015 | 672 | 0.210 |
Why?
| | Nutrition Surveys | 1 | 2024 | 117 | 0.210 |
Why?
| | Eukaryotic Initiation Factor-2B | 1 | 2003 | 5 | 0.210 |
Why?
| | Accidental Falls | 1 | 2004 | 105 | 0.210 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2002 | 7 | 0.200 |
Why?
| | Reference Values | 6 | 2017 | 313 | 0.200 |
Why?
| | Membrane Fusion | 1 | 2022 | 10 | 0.200 |
Why?
| | Carbohydrate Metabolism | 2 | 2019 | 23 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 3 | 2019 | 78 | 0.200 |
Why?
| | Tyrosine | 4 | 2022 | 87 | 0.200 |
Why?
| | Weightlessness | 1 | 2002 | 13 | 0.200 |
Why?
| | Vasodilator Agents | 1 | 2003 | 96 | 0.200 |
Why?
| | Splanchnic Circulation | 1 | 2002 | 34 | 0.200 |
Why?
| | Space Flight | 1 | 2002 | 32 | 0.200 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 18 | 0.200 |
Why?
| | Polymers | 1 | 2022 | 49 | 0.200 |
Why?
| | GTP-Binding Proteins | 1 | 2022 | 85 | 0.190 |
Why?
| | Alaska | 2 | 2020 | 24 | 0.190 |
Why?
| | Diet, High-Fat | 2 | 2024 | 236 | 0.190 |
Why?
| | Reindeer | 1 | 2021 | 3 | 0.190 |
Why?
| | Calorimetry, Indirect | 4 | 2006 | 26 | 0.190 |
Why?
| | Age Factors | 6 | 2017 | 1132 | 0.190 |
Why?
| | Injections, Intramuscular | 3 | 2011 | 56 | 0.180 |
Why?
| | Autophagy | 2 | 2020 | 193 | 0.180 |
Why?
| | Mice, Knockout | 1 | 2024 | 879 | 0.180 |
Why?
| | Myostatin | 1 | 2021 | 10 | 0.180 |
Why?
| | Fasting | 4 | 2020 | 75 | 0.180 |
Why?
| | Lysine | 2 | 2017 | 89 | 0.180 |
Why?
| | Proteolipids | 1 | 2021 | 10 | 0.180 |
Why?
| | Leptin | 1 | 2022 | 148 | 0.180 |
Why?
| | Health Status | 2 | 2016 | 294 | 0.180 |
Why?
| | Glycogenolysis | 1 | 2020 | 10 | 0.180 |
Why?
| | Neoplasms | 1 | 2011 | 1325 | 0.180 |
Why?
| | Severity of Illness Index | 4 | 2017 | 1026 | 0.180 |
Why?
| | Prospective Studies | 5 | 2017 | 2481 | 0.170 |
Why?
| | Random Allocation | 2 | 2015 | 285 | 0.170 |
Why?
| | Palmitic Acid | 4 | 2005 | 22 | 0.170 |
Why?
| | Plant Proteins | 1 | 2021 | 71 | 0.170 |
Why?
| | Femoral Artery | 3 | 2007 | 103 | 0.170 |
Why?
| | Hyperphagia | 1 | 2020 | 9 | 0.170 |
Why?
| | Postoperative Care | 1 | 2021 | 104 | 0.170 |
Why?
| | Analysis of Variance | 6 | 2009 | 554 | 0.170 |
Why?
| | Hypoglycemia | 1 | 2020 | 59 | 0.170 |
Why?
| | Breast Feeding | 1 | 2022 | 197 | 0.170 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2020 | 29 | 0.170 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2020 | 7 | 0.170 |
Why?
| | Enteral Nutrition | 4 | 2006 | 154 | 0.170 |
Why?
| | Preoperative Care | 1 | 2021 | 173 | 0.160 |
Why?
| | RNA, Messenger | 2 | 2022 | 1132 | 0.160 |
Why?
| | Health | 2 | 2012 | 21 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 202 | 0.160 |
Why?
| | Mouth | 1 | 2019 | 33 | 0.160 |
Why?
| | Fruit | 1 | 2020 | 128 | 0.160 |
Why?
| | Molecular Probe Techniques | 1 | 2019 | 9 | 0.160 |
Why?
| | Hindlimb | 3 | 2008 | 32 | 0.160 |
Why?
| | Radioisotope Dilution Technique | 3 | 2004 | 12 | 0.160 |
Why?
| | Military Medicine | 1 | 2019 | 24 | 0.160 |
Why?
| | Evaluation Studies as Topic | 1 | 2019 | 105 | 0.160 |
Why?
| | Palmitoylcarnitine | 2 | 2011 | 7 | 0.160 |
Why?
| | Intestinal Absorption | 1 | 2019 | 46 | 0.160 |
Why?
| | Water | 1 | 2019 | 82 | 0.160 |
Why?
| | Altitude Sickness | 2 | 2012 | 8 | 0.160 |
Why?
| | Proteome | 1 | 2020 | 171 | 0.150 |
Why?
| | Jejunum | 1 | 2019 | 55 | 0.150 |
Why?
| | Hypoalbuminemia | 1 | 2018 | 4 | 0.150 |
Why?
| | United States | 4 | 2024 | 5192 | 0.150 |
Why?
| | Basal Metabolism | 3 | 2020 | 33 | 0.150 |
Why?
| | HIV Infections | 1 | 2022 | 389 | 0.150 |
Why?
| | Lung | 1 | 2002 | 509 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2022 | 333 | 0.150 |
Why?
| | Occupational Diseases | 1 | 2019 | 85 | 0.150 |
Why?
| | Cholesterol | 3 | 2013 | 153 | 0.150 |
Why?
| | Oxandrolone | 2 | 2011 | 10 | 0.140 |
Why?
| | Inflammation | 4 | 2018 | 641 | 0.140 |
Why?
| | Alcohol Drinking | 1 | 2020 | 237 | 0.140 |
Why?
| | Intestinal Mucosa | 1 | 2019 | 224 | 0.140 |
Why?
| | Breakfast | 1 | 2017 | 16 | 0.140 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 108 | 0.140 |
Why?
| | Lower Extremity | 2 | 2009 | 100 | 0.140 |
Why?
| | Oxygen Consumption | 6 | 2019 | 198 | 0.140 |
Why?
| | Injections, Intradermal | 2 | 2007 | 14 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 2017 | 91 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2012 | 130 | 0.140 |
Why?
| | Quadriceps Muscle | 1 | 2017 | 47 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2017 | 66 | 0.130 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 71 | 0.130 |
Why?
| | Endpoint Determination | 1 | 2016 | 25 | 0.130 |
Why?
| | Athletic Performance | 1 | 2016 | 33 | 0.130 |
Why?
| | Egg Proteins, Dietary | 1 | 2016 | 2 | 0.130 |
Why?
| | Food Quality | 1 | 2016 | 2 | 0.130 |
Why?
| | Physical Fitness | 2 | 2014 | 57 | 0.130 |
Why?
| | Mice | 6 | 2024 | 5949 | 0.130 |
Why?
| | Chromatography, Liquid | 2 | 2008 | 240 | 0.130 |
Why?
| | Rest | 2 | 2007 | 60 | 0.130 |
Why?
| | Hyperemia | 1 | 2015 | 17 | 0.120 |
Why?
| | Chronic Disease | 4 | 2017 | 586 | 0.120 |
Why?
| | Forearm | 1 | 2015 | 32 | 0.120 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2008 | 253 | 0.120 |
Why?
| | Constriction | 2 | 2007 | 8 | 0.120 |
Why?
| | Tissue Donors | 2 | 2007 | 126 | 0.120 |
Why?
| | Microdialysis | 2 | 2005 | 18 | 0.120 |
Why?
| | Waist Circumference | 1 | 2015 | 21 | 0.120 |
Why?
| | Capillaries | 2 | 2007 | 50 | 0.120 |
Why?
| | Hand Strength | 1 | 2015 | 23 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2008 | 1678 | 0.110 |
Why?
| | Femoral Vein | 2 | 2005 | 38 | 0.110 |
Why?
| | NF-kappa B | 2 | 2007 | 322 | 0.110 |
Why?
| | Radioactive Tracers | 2 | 2019 | 9 | 0.110 |
Why?
| | Endothelium, Vascular | 1 | 2015 | 246 | 0.110 |
Why?
| | Logistic Models | 2 | 2015 | 925 | 0.110 |
Why?
| | Weight Gain | 2 | 2022 | 240 | 0.110 |
Why?
| | Proline | 2 | 2004 | 31 | 0.110 |
Why?
| | Exercise Test | 3 | 2019 | 141 | 0.110 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 192 | 0.110 |
Why?
| | Motor Activity | 3 | 2010 | 223 | 0.110 |
Why?
| | Pulmonary Edema | 2 | 2004 | 15 | 0.110 |
Why?
| | Walking | 1 | 2014 | 104 | 0.110 |
Why?
| | Carbohydrates | 2 | 2019 | 41 | 0.100 |
Why?
| | Amino Acid Sequence | 2 | 2022 | 578 | 0.100 |
Why?
| | Extremities | 1 | 2013 | 33 | 0.100 |
Why?
| | Risk Assessment | 4 | 2017 | 1327 | 0.100 |
Why?
| | Oxygen | 2 | 2006 | 336 | 0.100 |
Why?
| | Arginase | 1 | 2012 | 38 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2017 | 2279 | 0.100 |
Why?
| | Altitude | 1 | 2012 | 16 | 0.100 |
Why?
| | Nitric Oxide Synthase | 2 | 2012 | 62 | 0.100 |
Why?
| | Cystic Fibrosis | 2 | 2013 | 154 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2012 | 111 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2012 | 46 | 0.100 |
Why?
| | Organ Size | 1 | 2012 | 228 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 261 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2015 | 299 | 0.090 |
Why?
| | Glucose Tolerance Test | 3 | 2010 | 60 | 0.090 |
Why?
| | Cell Line | 2 | 2004 | 1030 | 0.090 |
Why?
| | Pulmonary Artery | 1 | 2012 | 150 | 0.090 |
Why?
| | Parenteral Nutrition | 2 | 2016 | 27 | 0.090 |
Why?
| | Breath Tests | 2 | 2007 | 40 | 0.080 |
Why?
| | Cushing Syndrome | 1 | 2009 | 9 | 0.080 |
Why?
| | Texas | 2 | 2007 | 143 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2022 | 595 | 0.080 |
Why?
| | Blood Pressure | 2 | 2017 | 537 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 134 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2007 | 139 | 0.080 |
Why?
| | Antiphospholipid Syndrome | 1 | 2009 | 9 | 0.080 |
Why?
| | Cholesterol, VLDL | 1 | 2008 | 3 | 0.080 |
Why?
| | Body Surface Area | 2 | 2006 | 27 | 0.080 |
Why?
| | Polysomnography | 2 | 2020 | 73 | 0.080 |
Why?
| | Institutionalization | 1 | 2008 | 11 | 0.080 |
Why?
| | Cachexia | 1 | 2008 | 27 | 0.070 |
Why?
| | Satiation | 1 | 2008 | 8 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 54 | 0.070 |
Why?
| | Muscle Strength Dynamometer | 1 | 2008 | 12 | 0.070 |
Why?
| | Gene Expression Regulation | 4 | 2010 | 990 | 0.070 |
Why?
| | Fontan Procedure | 1 | 2009 | 68 | 0.070 |
Why?
| | Linear Models | 2 | 2009 | 287 | 0.070 |
Why?
| | Parenteral Nutrition Solutions | 2 | 2004 | 8 | 0.070 |
Why?
| | RNA, Transfer | 1 | 2007 | 13 | 0.070 |
Why?
| | Citric Acid Cycle | 1 | 2007 | 18 | 0.070 |
Why?
| | Solutions | 2 | 2004 | 24 | 0.070 |
Why?
| | Sodium Bicarbonate | 1 | 2007 | 10 | 0.070 |
Why?
| | Ketoconazole | 1 | 2007 | 10 | 0.070 |
Why?
| | Electrolytes | 2 | 2004 | 26 | 0.070 |
Why?
| | Sleep | 2 | 2020 | 187 | 0.070 |
Why?
| | Space Simulation | 1 | 2007 | 2 | 0.070 |
Why?
| | Placebos | 2 | 2004 | 85 | 0.070 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2009 | 98 | 0.070 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 205 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 1884 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 251 | 0.070 |
Why?
| | Saliva | 1 | 2007 | 56 | 0.070 |
Why?
| | Gait | 1 | 2008 | 88 | 0.070 |
Why?
| | Acute Disease | 2 | 2019 | 373 | 0.070 |
Why?
| | Virus Latency | 1 | 2007 | 53 | 0.070 |
Why?
| | Trauma Severity Indices | 1 | 2007 | 51 | 0.070 |
Why?
| | Sex Factors | 2 | 2020 | 727 | 0.070 |
Why?
| | Cell Compartmentation | 1 | 2006 | 10 | 0.070 |
Why?
| | RNA | 1 | 2007 | 168 | 0.070 |
Why?
| | Styrenes | 1 | 2006 | 2 | 0.070 |
Why?
| | Siloxanes | 1 | 2006 | 2 | 0.070 |
Why?
| | Risk Factors | 4 | 2019 | 3889 | 0.060 |
Why?
| | Occlusive Dressings | 1 | 2006 | 6 | 0.060 |
Why?
| | Osmolar Concentration | 2 | 2003 | 62 | 0.060 |
Why?
| | APACHE | 1 | 2006 | 25 | 0.060 |
Why?
| | Administration, Topical | 1 | 2006 | 61 | 0.060 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2006 | 35 | 0.060 |
Why?
| | Hepatomegaly | 1 | 2006 | 7 | 0.060 |
Why?
| | Bandages | 1 | 2006 | 28 | 0.060 |
Why?
| | Methods | 1 | 2005 | 52 | 0.060 |
Why?
| | Carbohydrate Sequence | 1 | 2005 | 10 | 0.060 |
Why?
| | Anti-Infective Agents, Local | 1 | 2006 | 31 | 0.060 |
Why?
| | Creatinine | 1 | 2006 | 150 | 0.060 |
Why?
| | Injury Severity Score | 1 | 2006 | 167 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 166 | 0.060 |
Why?
| | Reference Standards | 1 | 2005 | 54 | 0.060 |
Why?
| | Infusions, Intra-Arterial | 1 | 2005 | 13 | 0.060 |
Why?
| | Pressure Ulcer | 1 | 2005 | 16 | 0.060 |
Why?
| | Life Style | 1 | 2006 | 145 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2005 | 6 | 0.060 |
Why?
| | Milk | 1 | 2006 | 81 | 0.060 |
Why?
| | Body Water | 1 | 2005 | 27 | 0.060 |
Why?
| | Arteries | 2 | 2004 | 92 | 0.060 |
Why?
| | Hematocrit | 1 | 2005 | 44 | 0.060 |
Why?
| | Blood Coagulation Tests | 1 | 2005 | 20 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2007 | 273 | 0.060 |
Why?
| | Fluorocarbons | 1 | 2005 | 61 | 0.060 |
Why?
| | Ecchymosis | 1 | 2004 | 8 | 0.060 |
Why?
| | Osteoporosis | 1 | 2006 | 162 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 488 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2009 | 412 | 0.060 |
Why?
| | Blood Specimen Collection | 1 | 2004 | 35 | 0.060 |
Why?
| | Signal Transduction | 3 | 2020 | 1671 | 0.060 |
Why?
| | Biological Transport, Active | 1 | 2004 | 30 | 0.060 |
Why?
| | Muscle Fatigue | 1 | 2004 | 15 | 0.060 |
Why?
| | Locomotion | 1 | 2004 | 85 | 0.060 |
Why?
| | Hematoma | 1 | 2004 | 65 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 778 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2004 | 183 | 0.060 |
Why?
| | Catheterization | 1 | 2004 | 96 | 0.060 |
Why?
| | Culture Media | 1 | 2004 | 98 | 0.060 |
Why?
| | Interleukin-18 | 1 | 2024 | 27 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 90 | 0.050 |
Why?
| | Physical Education and Training | 1 | 2004 | 23 | 0.050 |
Why?
| | Iontophoresis | 1 | 2003 | 11 | 0.050 |
Why?
| | Albumins | 1 | 2004 | 32 | 0.050 |
Why?
| | Amino Acid Transport Systems | 1 | 2003 | 5 | 0.050 |
Why?
| | Pilocarpine | 1 | 2003 | 26 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 293 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2004 | 104 | 0.050 |
Why?
| | Cell Count | 1 | 2004 | 149 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 118 | 0.050 |
Why?
| | Injections, Intra-Arterial | 1 | 2003 | 13 | 0.050 |
Why?
| | Nitric Oxide Donors | 1 | 2003 | 9 | 0.050 |
Why?
| | Nitroprusside | 1 | 2003 | 11 | 0.050 |
Why?
| | Adaptation, Physiological | 1 | 2004 | 110 | 0.050 |
Why?
| | Cough | 1 | 2003 | 55 | 0.050 |
Why?
| | Regression Analysis | 1 | 2004 | 401 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2004 | 87 | 0.050 |
Why?
| | Computer Simulation | 1 | 2004 | 290 | 0.050 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 459 | 0.050 |
Why?
| | Time | 1 | 2003 | 28 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 14 | 0.050 |
Why?
| | Coloring Agents | 1 | 2003 | 69 | 0.050 |
Why?
| | Hydroxyproline | 1 | 2003 | 19 | 0.050 |
Why?
| | Indocyanine Green | 1 | 2003 | 33 | 0.050 |
Why?
| | Ventricular Dysfunction | 1 | 2003 | 11 | 0.050 |
Why?
| | Carbazoles | 1 | 2003 | 18 | 0.050 |
Why?
| | HIV Envelope Protein gp41 | 1 | 2022 | 5 | 0.050 |
Why?
| | Body Constitution | 1 | 2002 | 12 | 0.050 |
Why?
| | Weightlessness Countermeasures | 1 | 2002 | 2 | 0.050 |
Why?
| | Transposition of Great Vessels | 1 | 2003 | 26 | 0.050 |
Why?
| | Cell Membrane | 1 | 2003 | 245 | 0.050 |
Why?
| | Drug Combinations | 1 | 2003 | 132 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2005 | 220 | 0.050 |
Why?
| | Fish Oils | 1 | 2002 | 14 | 0.050 |
Why?
| | Linoleic Acid | 1 | 2002 | 16 | 0.050 |
Why?
| | Phosphatidylcholines | 1 | 2002 | 27 | 0.050 |
Why?
| | Endotoxins | 1 | 2002 | 21 | 0.050 |
Why?
| | Blood Proteins | 1 | 2023 | 85 | 0.050 |
Why?
| | Ear | 1 | 2002 | 17 | 0.050 |
Why?
| | Microspheres | 1 | 2002 | 21 | 0.050 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2002 | 13 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2002 | 73 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 31 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2022 | 38 | 0.050 |
Why?
| | Ribosomal Proteins | 1 | 2022 | 24 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2002 | 77 | 0.050 |
Why?
| | Drug Synergism | 1 | 2002 | 150 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 891 | 0.050 |
Why?
| | Peptides | 1 | 2022 | 223 | 0.050 |
Why?
| | Thinness | 2 | 2016 | 44 | 0.050 |
Why?
| | Neutrophils | 1 | 2002 | 147 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 169 | 0.040 |
Why?
| | Gene Expression | 1 | 2003 | 618 | 0.040 |
Why?
| | Food | 1 | 2020 | 66 | 0.040 |
Why?
| | Orthopedic Procedures | 1 | 2021 | 71 | 0.040 |
Why?
| | Ceramides | 1 | 2020 | 34 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 256 | 0.040 |
Why?
| | Dexamethasone | 1 | 2022 | 438 | 0.040 |
Why?
| | Protein Kinases | 1 | 2020 | 72 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2022 | 340 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 169 | 0.040 |
Why?
| | Occupational Health | 1 | 2019 | 66 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2018 | 27 | 0.040 |
Why?
| | Rats, Zucker | 2 | 2010 | 73 | 0.040 |
Why?
| | Apoptosis | 1 | 2003 | 1119 | 0.040 |
Why?
| | Body Weights and Measures | 1 | 2017 | 17 | 0.040 |
Why?
| | Artifacts | 1 | 2018 | 55 | 0.040 |
Why?
| | Hunger | 1 | 2017 | 15 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2004 | 560 | 0.040 |
Why?
| | Animal Structures | 1 | 2017 | 3 | 0.040 |
Why?
| | Clinical Chemistry Tests | 1 | 2017 | 3 | 0.040 |
Why?
| | Withholding Treatment | 1 | 2017 | 19 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2017 | 29 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 585 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 721 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 2017 | 13 | 0.030 |
Why?
| | Venae Cavae | 1 | 2017 | 9 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2017 | 34 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 115 | 0.030 |
Why?
| | Sus scrofa | 1 | 2017 | 39 | 0.030 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2017 | 65 | 0.030 |
Why?
| | Glycogen | 2 | 2010 | 44 | 0.030 |
Why?
| | Mutation | 1 | 2022 | 1347 | 0.030 |
Why?
| | Caffeine | 1 | 2016 | 61 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 2017 | 84 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2020 | 807 | 0.030 |
Why?
| | Research Design | 1 | 2017 | 359 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 125 | 0.030 |
Why?
| | Pregnancy | 1 | 2022 | 2680 | 0.030 |
Why?
| | Multienzyme Complexes | 2 | 2006 | 40 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 181 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 944 | 0.030 |
Why?
| | Cardiac Catheterization | 2 | 2009 | 232 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2021 | 1068 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 443 | 0.030 |
Why?
| | Octreotide | 1 | 2013 | 9 | 0.030 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2013 | 7 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2015 | 187 | 0.030 |
Why?
| | Intra-Abdominal Fat | 1 | 2013 | 21 | 0.030 |
Why?
| | Ubiquitin | 2 | 2003 | 47 | 0.030 |
Why?
| | Medicare | 1 | 2015 | 274 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2015 | 215 | 0.020 |
Why?
| | Colorado | 1 | 2012 | 25 | 0.020 |
Why?
| | Rats | 2 | 2010 | 3220 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 110 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 262 | 0.020 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2010 | 13 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2010 | 19 | 0.020 |
Why?
| | Amino-Acid N-Acetyltransferase | 1 | 2010 | 2 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 235 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 108 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 374 | 0.020 |
Why?
| | Protein-Energy Malnutrition | 1 | 2009 | 19 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2012 | 6607 | 0.020 |
Why?
| | Chest Pain | 1 | 2009 | 57 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 346 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2012 | 321 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2011 | 747 | 0.020 |
Why?
| | Movement | 1 | 2008 | 82 | 0.020 |
Why?
| | Thermogenesis | 1 | 2008 | 29 | 0.020 |
Why?
| | Patient Discharge | 1 | 2010 | 330 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2007 | 28 | 0.020 |
Why?
| | Electrocardiography | 1 | 2009 | 268 | 0.020 |
Why?
| | Diglycerides | 1 | 2006 | 10 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2009 | 367 | 0.020 |
Why?
| | Lipolysis | 1 | 2006 | 11 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2006 | 31 | 0.020 |
Why?
| | Aerobiosis | 1 | 2006 | 13 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2006 | 155 | 0.020 |
Why?
| | Anticoagulants | 1 | 2009 | 270 | 0.020 |
Why?
| | Cohort Studies | 1 | 2010 | 1542 | 0.020 |
Why?
| | Hematinics | 1 | 2005 | 15 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 528 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 64 | 0.010 |
Why?
| | Erythropoietin | 1 | 2005 | 50 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2005 | 124 | 0.010 |
Why?
| | Drug Utilization | 1 | 2005 | 78 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 25 | 0.010 |
Why?
| | Hindlimb Suspension | 1 | 2004 | 37 | 0.010 |
Why?
| | Gastric Bypass | 1 | 2004 | 20 | 0.010 |
Why?
| | Diaphragm | 1 | 2004 | 33 | 0.010 |
Why?
| | 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2003 | 2 | 0.010 |
Why?
| | Veins | 1 | 2004 | 74 | 0.010 |
Why?
| | Bronchiectasis | 1 | 2003 | 8 | 0.010 |
Why?
| | Complement System Proteins | 1 | 2003 | 32 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2003 | 52 | 0.010 |
Why?
| | Acidosis | 1 | 2003 | 41 | 0.010 |
Why?
| | Caspase 3 | 1 | 2003 | 95 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 483 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 2003 | 92 | 0.010 |
Why?
| | Extracellular Space | 1 | 2003 | 37 | 0.010 |
Why?
| | Food Additives | 1 | 2003 | 7 | 0.010 |
Why?
| | Protein Array Analysis | 1 | 2003 | 24 | 0.010 |
Why?
| | Organic Chemicals | 1 | 2003 | 15 | 0.010 |
Why?
| | Caspases | 1 | 2003 | 104 | 0.010 |
Why?
| | Infant | 1 | 2012 | 3733 | 0.010 |
Why?
| | Wound Infection | 1 | 2003 | 32 | 0.010 |
Why?
| | Cysteine Endopeptidases | 1 | 2003 | 67 | 0.010 |
Why?
| | Comorbidity | 1 | 2004 | 625 | 0.010 |
Why?
| | Diuresis | 1 | 2002 | 14 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2003 | 117 | 0.010 |
Why?
| | Stroke Volume | 1 | 2003 | 155 | 0.010 |
Why?
| | Norepinephrine | 1 | 2002 | 112 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 405 | 0.010 |
Why?
| | Recurrence | 1 | 2003 | 672 | 0.010 |
Why?
| | Receptors, Androgen | 1 | 2002 | 46 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 639 | 0.010 |
Why?
| | Prostate | 1 | 2002 | 116 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 1062 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 590 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2003 | 1046 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 1165 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2003 | 1105 | 0.010 |
Why?
|
|
Wolfe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|